ArticleCureus2025
Intra-arterial Bevacizumab in Adult Patients With Steroid-Refractory Cerebral Radiation Necrosis: An Observational Study of Clinical Indications and Outcomes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Cerebral radiation necrosis (RN) is a chronic inflammatory process that may develop following radiotherapy for a primary or metastatic brain tumor or arteriovenous malformation (AVM). A single infusion dose of intra-arterial (IA) bevacizumab (BV) is a viable option. The aim of this study was to assess the safety and efficacy of IA BV infusion in patients with steroid-refractory cerebral RN. Materials and methods A total of 33 patients with imaging-confirmed brain RN underwent at least one IA BV infusion over a 9-year duration. BV was administered as a single 2.5 mg/kg (n=24) or 5.0 mg/kg (n=9) infusion dose. Results Diagnoses included brain metastasis (17 (51.5%)), AVM (10 (30.3%)), and primary brain tumors (six (18%)). All patients experienced either complete relief or significant symptom improvement after the IA IV infusion. The initial brain MRIs performed following the IA BV infusion revealed a decreased size of the RN in all patients. Two patients had minimal side effects. Of the 16 (48.5%) patients who experienced an RN recurrence, 10 underwent a repeat IA BV infusion. The mean duration between the first IA BV infusion and last follow-up was 23.2 months (range: 0.1-85.2 months). Age (p = 0.00587), tumor pathology (p = 0.03509), and BV dosage (p = 0.02420) were significant predictors of RN recurrence. Conclusions IA infusion of BV was well-tolerated by all patients, with substantial clinical and radiological improvement. Further research is needed to explore additional factors that may impact the effectiveness of BV treatment in RN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.